ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
FAIL · Does not pass the screen
31.00 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
ArriVent BioPharma, Inc. holds its Markdown at $31.00. The statistical read favours the sellers, held for 12 days.
As held on the ledger · 2026-08-27
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 12 days
Price at the screen
$31.00
Valuation
N/A trailing · -8.15 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.37
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.00%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
80.22%
Below 33%
Interest-bearing cash and securities are 80.2% of assets, above the one-third limit.
Fail
Receivables
13.69%
Below 49%
Money owed to the company is 13.7% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 45.2% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +45% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical stage cancer bets with missing numbers
Picture a lab racing to turn one promising molecule into a cancer drug that patients actually need. ArriVent is exactly that story, yet it posts zero profit, negative returns on equity and a forward multiple that signals losses ahead. With no financial ratios available the ethical screen simply cannot clear it.
We therefore pass. Analyst targets sit above the current price and the lead candidate looks interesting on paper, but the absence of usable data leaves us unable to judge governance or long term sustainability.
Risks sit in the usual biotech traps of trial failure, dilution and cash burn that never turns into revenue. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AVBP trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
2026-07-22Markdown$33.19+8.7%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 8.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
2026-07-18Markdown$30.54+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (12 analysts) rates it strong buy, with a mean price target of $42.
2026-07-03Markdown$30.54+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$30.54Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
